Randomized Placebo-Controlled Trial of Baclofen for Cocaine Dependence: Preliminary Effects for Individuals With Chronic Patterns of Cocaine Use
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This screening trial evaluated whether the GABAB agonist baclofen demonstrated sufficient clinical efficacy to recommend an adequately powered trial of the medication as a pharmacotherapy for cocaine dependence. METHOD: Participants with cocaine dependence verified by the Structured Clinical Interview for DSM-IV were randomly assigned to baclofen (N = 35; 20 mg t.i.d.) or placebo conditions (N = 35; identical in appearance and dosage rate) using a 2-group, experimental, 16-week double-blind design featuring thrice-weekly cognitive-behavioral drug counseling groups. Outcomes were retention, cocaine use, cocaine craving, and adverse events. RESULTS: A generalized estimating equation (GEE) model showed that participants assigned to receive baclofen demonstrated statistically significant reductions in cocaine use over those assigned to receive placebo as indicated by urine drug screening results (chi(2) = 5.34, df = 1, p =.021). Confirming the GEE model, longitudinal analyses showed that participants assigned to receive baclofen demonstrated significant and stepwise increases in the probability of providing benzoylecgonine-free urine samples throughout the trial as the number of benzoylecgonine-positive samples increased during baseline (chi(2) = 10.63, df = 1, p =.001). Participants assigned to placebo demonstrated no such association. Univariate analyses of aggregates of urine drug screening showed generally favorable outcomes for baclofen, but not at statistically significant levels. There was no statistical significance observed for retention, cocaine craving, or incidence of reported adverse events by treatment condition. CONCLUSIONS: Project findings demonstrated initial clinical efficacy of baclofen over placebo in reducing cocaine use when delivered concurrent with thrice-weekly drug abuse counseling sessions. The effects of baclofen were particularly apparent for those participants with chronic levels of cocaine use at baseline and provide support for a full-scale efficacy trial for baclofen, especially among this subgroup of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jentsch, J. D., & Taylor, J. R. (1999) · Psychopharmacology · doi:10.1007/pl00005483 · Cited by 1,545 · cited 2×
“Participants also met none of the following exclusion criteria: (1) dependence on alcohol or other substances, current (SCID-verified); (2) current psychiatric disorder requiring treatment; ( 3 ) active medical conditions that interfere with participation (e.g., uncontrolled diabetes); (4) history of seizures; (5) uns…”
BackgroundMethodAn intensive outpatient approach for cocaine abuse treatment
Rawson, R. A., Shoptaw, S. J., Obert, J. L., McCann, M. J., Hasson, A. L., Marinelli-Casey, P. J., Brethen, P. R., & Ling, W. (1995) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(94)00080-b · Cited by 197
Self-citation
Cited by
Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101
Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D'Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 685
Drug addiction: the neurobiology of disrupted self-control
Baler, R. D., & Volkow, N. D. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.005 · Cited by 640
Drug addiction: the neurobiology of behaviour gone awry
Volkow, N. D., & Li, T.-K. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1539 · Cited by 625
Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Neurobiologic processes in drug reward and addiction
Adinoff, B. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490910844 · Cited by 546
Goodman, A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 413
Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O’Brien, C. P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1423 · Cited by 405
“The GABA B agonist baclofen has also been reported to reduce cocaine use (70), and it is now the subject of a multiclinic trial.”
BackgroundPharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., & Nielsen, D. A. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.1 · Cited by 391
Baskerville, T. A., & Douglas, A. J. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00154.x · Cited by 377
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Shoptaw, S., Reback, C. J., Peck, J. A., Yang, X., Rotheram-Fuller, E., Larkins, S., Veniegas, R. C., Freese, T. E., & Hucks-Ortiz, C. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.10.004 · Cited by 313
Self-citationControversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270
“Baclofen has also shown promise in a pilot clinical trial for cocaine dependence (Shoptaw et al. 2003), but more recent clinical work suggests that baclofen’s effects may not be sufficiently robust to reduce ongoing cocaine abuse (S.”
BackgroundAgonist-like, replacement pharmacotherapy for stimulant abuse and dependence
Grabowski, J., Shearer, J., Merrill, J., & Negus, S. S. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.06.018 · Cited by 257
Monoamine transporters and psychostimulant addiction
Howell, L. L., & Kimmel, H. L. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.003 · Cited by 255
Bridges, R., Lutgen, V., Lobner, D., & Baker, D. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003889 · Cited by 205
“…D-serine, glutamate, hevin, kynurenic acid, secreted protein acidic and rich in cysteine, and thrombospondins (Beattie et al., 2002; Newman, 2003; Shoptaw et al., 2003; Christopherson et al., 2005; Stellwagen and Malenka, 2006; 1Abbreviations: ALS, amyotrophic lateral sclerosis; AMPA,…”
BackgroundAn open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study
Mardikian, P. N., LaRowe, S. D., Hedden, S., Kalivas, P. W., & Malcolm, R. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.10.001 · Cited by 179
Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis
Chan, B., Kondo, K., Freeman, M., Ayers, C., Montgomery, J., & Kansagara, D. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05074-8 · Cited by 150
Bingeing rats: A model of intermittent excessive behavior?
Corwin, R. L. (2006) · Appetite · doi:10.1016/j.appet.2004.09.002 · Cited by 134
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Repetitive transcranial magnetic stimulation and drug addiction
Barr, M. S., Farzan, F., Wing, V. C., George, T. P., Fitzgerald, P. B., & Daskalakis, Z. J. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.618827 · Cited by 78
“…trials have also demonstrated a reduction in cocaine cravings and cocaine use following the administration of baclofen (Haney et al., 2006; Ling et al., 1998; Shoptaw et al., 2003), thus strengthening the consideration of GABA B as a therapeutic target in the treatment of cocaine addiction.”
BackgroundA review of psychological and pharmacological treatment options for methamphetamine dependence
Ciketic, S., Hayatbakhsh, M. R., Doran, C. M., Najman, J. M., & McKetin, R. (2012) · Journal of Substance Use · doi:10.3109/14659891.2011.592900 · Cited by 36
Purgianto, A., Loweth, J. A., Miao, J. J., Milovanovic, M., & Wolf, M. E. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.014 · Cited by 11
Metadata
- Authors
- Shoptaw, S., Yang, X., Rotheram-Fuller, E. J., Hsieh, Y.-C. M., Kintaudi, P. C., Charuvastra, V. C., & Ling, W.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-12-15
- Volume
- 64
- Issue
- 12
- Pages
- 1440-1448
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2104314642
- Cited by
- 215
- References
- 2
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.